MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z
  • Magnetic resonance characteristic of Parkinson’s disease based on the presence of cognitive impairment

    F.B. Doniyorova (Tashkent, Uzbekistan)

  • Magnetic resonance diffusion tensor imaging for the pedunculopontine nucleus: Correlation between neuroimaging and cytoarchitectonic features

    A.T.D.L. Alho, C. Hamani, E.J.L. Alho, R.E. da Silva, G.A.B. dos Santos, R.C. Neves, C.M.M. Araujo, G. Magalhães, L.T. Grinberg, H. Heinsen, E.T. Fonoff, E. Amaro-Junior (São Paulo, Brazil)

  • Magnetic resonance imaging and pyramidal impairment in Huntington disease

    A. Sanguinetti, S. Lescano, M. Cesarini, J. Etcheverry, E. Gatto (Buenos Aires, Argentina)

  • Magnetic resonance imaging in spinocerebellar ataxias: A systematic review

    J.A. Saute, E. Reckziegel, M.C. França Jr, T.J.R. Ribeiro, L.M. Vedolin, L.B. Jardim, A.A. Klaes (Porto Alegre, Brazil)

  • Magnetic resonance imaging of nigrosome-1 in the diagnosis of early Parkinson’s: Initial results of the Parkinson’s magnetic imaging repository (PaMIR)

    S.T. Schwarz, Y. Xing, A. Martin Bastida, C. Lakmali Sugathapala, M. Silverdale, J. Mclean, R. Jampana, N. Bajaj, D. Burn, P. Piccini, D. Grosset, D.P. Auer (Nottingham, United Kingdom)

  • Maintenance of balance function in patients with HD treated with deutetrabenazine, as measured by Berg balance test (BBT) in First-HD

    D.O. Claassen, D. Oakes, D. Stamler, V. Sung, C.M. Testa, S. Frank, On behalf of the First-HD HSG Investigators (Nashville, TN, USA)

  • Manganese-induced parkinsonism and motor neuron damage- Can there be a relationship?

    I. Giorgishvili, N. Lobjanidze, N. Akiashvili, M. Janelidze, M. Beridze (Tbilisi, Georgia)

  • Manual MRI morphometry in Parkinsonian syndromes

    L. Möller, J. Kassubek, M. Südmeyer, R. Hilker, E. Hattingen, K. Egger, F. Amtage, G. Respondek, M. Stamelou, A. Schnitzler, W.H. Oertel, S. Knake, H.J. Huppertz, G.U. Höglinger (Marburg, Germany)

  • May early introduction of dopaminergic agonists improve simptoms after ischemic stroke? The interim report

    J. Kobal, Z. Melik, K. Cankar (Ljubljana, Slovenia)

  • May substantia nigra volume asymmetry be an indicator of motor asymmetry in Parkinson’s disease? A retrospective analysis

    N.F. Durmaz, M. Yorubulut, C.M. Akbostanci (Ankara, Turkey)

  • Meaningful life attitudes support positive coping in patients with idiopathic Parkinson’s disease

    S. Gräber, J. Meinhardt, E. Schäffer, A. Apel, D. Berg (Tübingen, Germany)

  • Measurement of effect of variable deep brain stimulation (DBS) frequencies on static postural control in Parkinson’s disease (PD) patients with bilateral STN or GPi stimulators by employing force plate

    A. Deep, A. Lieberman, R. Dhall, T. Lockhart, S. Shafer, C. Frames, N. Tateuchi, E. Simpson, M. McCauley, N. Krishnamurthi, S. Syed (Phoenix, AZ, USA)

  • Measurement of night time sleep using an accelerometry based system

    M. Horne, S. McGregor, G. Hamilton, D. O'Driscoll, R. Blaze, P. Churchward (Parkville, Australia)

  • Measuring interdependence of the health status of people with Parkinson’s disease and their spouses

    F. Noubary, S.D. Gunnery, E.M. Naumova, M. Saint-Hilaire, C.A. Thomas, L. Tickle-Degnen (Boston, MA, USA)

  • Medical cannabis for the treatment of Tourette syndrome: A descriptive analysis of 24 patients

    S. Arad, L. Bar-Lev Schleider, J. Knaani, H. Shabtai, Y. Balash, A. Ezra, N. Giladi, T. Gurevich (Tel-Aviv, Israel)

  • Medication errors: The role of the nurse in an interdisciplinary home visit program for advanced Parkinson’s disease patients

    S.E. Oyler, J.E. Fleisher, M.M. Sweeney, A.C. Lemen, A. Fazl, G. Dacpano, R.M. Gilbert, A. Di Rocco, J. Chodosh (New York, NY, USA)

  • Medication use patterns vary across expert Parkinson’s disease clinics

    P. Schmidt, F. Cubillos, T. Simuni, C. Marras, T. Davis, E.C. Nelson (Miami, FL, USA)

  • Medicinal cannabis for Parkinson’s disease: A survey of practices, beliefs, and attitudes among providers at NPF centers of excellence

    D. Bega, T. Simuni, M.S. Okun, P. Schmidt (Chicago, IL, USA)

  • MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum

    G. Chen, S. Nie, K. Ma, C. Han, Y. Xu, Z. Zhang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

  • Memory compensation strategies in patients with Parkinson’s disease

    C.C. Walton, J.Y.Y. Szeto, L. Mowszowski, S.J.G. Lewis, S.L. Naismith (Sydney, Australia)

  • Mental simulation of whole-body movements in patients with isolated cervical dystonia

    M. Esposito, C. Vitale, F. Falco, S. Corvino, R. Allocca, S. Peluso, G. Santangelo, M. Conson (Naples, Italy)

  • Metabolic brain changes related to specific cognitive impairment in non-demented Parkinson’s disease patients

    M. Trošt, S. Brezovar, C.C. Tang, D. Eidelberg, N. Zupancic Kriznar, M. Gregoric Kramberger, P. Tomše, Z. Pirtošek (Ljubljana, Slovenia)

  • Micro-RNA in cerebrospinal fluid as a biomarker for early diagnosis, differential diagnosis and prognostic marker in Parkinson’s disease

    A. Fischbach, A.E. Roser, F. Maass, M. Börger, M. Bähr, I. Zerr, A. Fischer, P. Lingor (Göttingen, Germany)

  • Microglia P2Y6 receptor is related to Parkinson’s disease and involved in the neuroinflammatory process

    X. Yang, Y. Lou, X. Wang, G. Liu, Y. Qian, J. Ding, S. Chen, Q. Xiao (Shanghai, People's Republic of China)

  • MicroRNA as diagnostic biomarkers in Parkinson’s disease and multiple system atrophy

    C.C. Starhof, K. Winge, N. Heegaard, A.M. Hejl (København, Denmark)

  • Midbrain atrophy differentially progresses between Richardson’s Syndrome, progressive supranuclear palsy-parkinsonism and Parkinson’s disease: Longitudinal MRI study

    Y.E. Huh, M. Hwang, J.K. Park, J.W. Cho (Seoul, Korea)

  • Mild cognitive impairment in Parkinson’s disease: Impact on caregiver outcomes

    J.Y.Y. Szeto, M. Gilat, C.C. Walton, L. Mowszowski, S.L. Naismith, S.J.G. Lewis (Sydney, Australia)

  • Mild cognitive impairment is linked with white matter degeneration in the cortico-subcortical tracts in patients with Parkinson’s disease

    A. Hanganu, J.C. Houde, V.S. Fonov, C. Degroot, B. Mejia-Constain, A.L. Lafontaine, V. Soland, S. Chouinard, L.D. Collins, M. Descoteaux, O. Monchi (Calgary, Canada)

  • Mild mitochondrial impairment promotes corticostriatal synaptic plasticity alterations in PINK1 heterozygous knockout mice

    P. Imbriani, G. Martella, G. Madeo, M. Maltese, V. Vanni, E. Ferraro, E.M. Valente, T. Schirinzi, L. Bonanni, J. Shen, N.B. Mercuri, P. Bonsi, A. Pisani (Rome, Italy)

  • Mild Parkinsonian signs and TIA/stroke

    J.L. Adams, N. Dahodwala (Rochester, NY, USA)

  • Mind the gap: Temporal discrimination and cervical dystonia

    A. Sadnicka, C. Daum, C. Cordivari, K.P. Bhatia, J.C. Rothwell, S. Manohar, M.J. Edwards (London, United Kingdom)

  • Minimal impact of “interleaving” on neuromodulation device battery drain when interleave frequency is halved

    Y.M. Fernandez, D.L. Caputo, D.P. Schneider, S.F. Danish, R.J. Dipaola, E.L. Hargreaves (New Brunswick, NJ, USA)

  • Minimizing levodopa titration period for Parkinson’s disease (PD)

    I. Thomas, M. Alam, D. Nyholm, M. Senek, J. Westin (Falun, Sweden)

  • Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)

    H. Shill, A. Agro, E.J. Pappert, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

  • Mirror movements in Moebius syndrome: Mirroring beyond movements

    H.J.S. Cho, P. Panyakaew, M. Hallett (Bethesda, MD, USA)

  • Mitochondrial cardiolipin couples electron transport between ubiquinone and complex I to rescue PINK1 deficiency

    M. Vos, A. Geens, L. Deaulmerie, J. Swerts, K. Craessaerts, P. Seibler, A. Rakovic, B. De Strooper, R. Efremov, V.A. Morais, C. Klein, P. Verstreken (Lübeck, Germany)

  • Mitochondrial dysfunction in skin fibroblasts from single heterozygous ATP13A2 (PARK9) mutation carriers

    J.S. Park, C. Klein, C.M. Sue (St. Leonards, Australia)

  • Mitochondrial Hsp90 inhibitor G-TTP triggers PINK1/parkin-dependent mitochondrial quality control

    F.C. Fiesel, J.D. Elle, H.R. Anneliese, H. Roman, S. Wolfdieter (Jacksonville, FL, USA)

  • Mitochondrial response precedes intracellular accumulation of α-synuclein in Parkinson’s disease

    I. Milenkovic, E. Dassler, M. Weber, G.G. Kovacs (Vienna, Austria)

  • Mitochondrial-nuclear interplay in single respiratory chain-deficient Parkinson’s disease neurons

    A. Grünewald, K.A. Rygiel, P.D. Hepplewhite, C.M. Morris, M. Picard, D.M. Turnbull (Belvaux, Luxembourg)

  • Mixed tremor with cryptogenic atrophy of dominant hemisphere, diagnostic and treatment challenges

    O.E. Turgunkhujaev, A.R. Khashimova (Tashkent, Uzbekistan)

  • MMSE and MoCA feasibility in Parkinson’s disease and dementia with Lewy bodies: A multicenter 1-year follow-up study

    R. Biundo, L. Weis, S. Bostantjopoulou, E. Stefanova, C. Falup-Pecurariu, M.G. Kramberger, G. Geurtsen, A. Antonini, D. Weintraub, D. Aarsland (Venice, Italy)

  • Mobile decision support system for nurse managment of deep brain stimulation

    G. Duffley, D. Martinez, J. Krueger, B. Lutz, M.S. Okun, C.R. Butson (Salt Lake City, UT, USA)

  • Modeling dementia with Lewy bodies using patient-derived neurons

    D.H. Adamowicz, J. Mertens, D.P. Salmon, D.R. Galasko, S. Roy, F.H. Gage (La Jolla, CA, USA)

  • Modeling trajectories of brain damage in progressive supranuclear palsy: A longitudinal multimodal MRI study

    F. Caso, F. Agosta, M. Lukic-Jecmenica, I. Petrovic, P. Valsasina, P.M. Ferraro, A. Meani, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)

  • Modelling spinocerebellar ataxia 15 with iPS cell derived neurons

    S. Wiethoff, C. Arber, S. Wray, Y. Zhi, R. Patani, H. Henry (London, United Kingdom)

  • Modulating neuronal activity in dopaminergic neurons to promote their survival

    M.A. Bernardi, N. Baffa-Trasci, O. Gershanik, M.E. Avale, J.E. Ferrario (Caba, Argentina)

  • Modulation and mechanism for the neuroprotective effects of 17-beta-estradiol: Relevance to depressive symptoms in Parkinson’s disease

    P. Kumar, N. Baquer (New Delhi, India)

  • Modulation of local field potentials during gait in the STN of patients with Parkinson’s disease

    F. Hell, J.H. Mehrkens, A. Plate, K. Bötzel (München, Germany)

  • Modulation of microglia function in the prion-like spreading of α-synuclein in the murine brain

    W.M. Wemheuer, P. Garcia, E. Konica, A. Masuch, S. Brioschi, K. Biber, A. Weihofen, H. Kollmus, K. Schughart, D. Coowar, R. Balling, M. Buttini (Esch-sur-Alzette, Luxembourg)

  • Modulation of thalamocortical network dynamics via deep brain stimulation in humans with Tourette syndrome

    J.B. Shute, P.J. Rossi, E. Opri, R. Molina, C. De Hemptinne, K.D. Foote, M.S. Okun, A. Gunduz (Gainesville, FL, USA)

  • Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease: Meta-analysis of individual participant data from seven prospective observational studies

    F. Yang, N.L. Pedersen, W. Ye, Z. Liu, M. Norberg, L. Forsgren, Y. Trolle Lagerros, R. Bellocco, L. Alfredsson, A. Knutsson, J.H. Jansson, R. Galanti, A.C.J. Lager, M. Araghi, M. Lundberg, C. Magnusson, K. Wirdefeldt (Stockholm, Sweden)

  • Molecular landscape of Parkinson’s disease reveals a key role for lipids and lipoproteins

    C.J.H.M. Klemann, G.J.M. Martens, M. Sharma, M.B. Martens, O. Isacson, T. Gasser, J.E. Visser, G. Poelmans (Nijmegen, Netherlands)

  • Monitoring dyskinesia severity using wearable sensor data

    J.F. Daneault, F.N. Golabchi, S.I. Lee, G. Vergara-Diaz, G. Ferreira Carvalho, E. Fabara, S. Sapienza, P. Bonato (Charlestown, MA, USA)

  • Monitoring oxidative stress and progression to cell death: From secretome to blood diagnosis

    S.I. Anjo, V.M. Mendes, M. Grãos, B. MAnadas (Cantanhede, Portugal)

  • Monoaminergic biomarkers of cognitive decline in Parkinson’s disease and Lewy body dementia

    S. van der Zee, Y. Vermeiren, T. Aerts, D. van Dam, M.J. Gerritsen, J.M. Spikman, T. van Laar, P.P. de Deyn (Groningen, Netherlands)

  • Morbidity and comorbidity of deep brain stimulation for Parkinson’s disease – A thirteen-years retrospective cohort study

    S.Y. Chen, Y.H. Pan, S.H. Lin (Hualien, Taiwan)

  • Mortality after deep brain stimulation surgery for patients with advanced Parkinson’s disease

    H.S. Ryu, S. You, M.J. Kim, Y.J. Kim, J. Kim, K. Kim, S.J. Chung (Seoul, Korea)

  • Motivators and barriers to participation in exercise in Parkinson’s disease

    M. Afshari, Y. Kianirad, D. Bega (Chicago, IL, USA)

  • Motor and non-motor symptoms in Parkinson’s disease: Correlation and impact on quality of life and activities of daily living

    P. Bugalho, T. Lampreia, R. Miguel, M. Mendonça, A. Caetano, R. Barbosa (Lisbon, Portugal)

  • Motor cortex neuroplasticity and learning following high-intensity interval exercise

    J.P. Coxon, E. Stavrinos (Melbourne, Australia)

  • Motor features and response to levodopa in Parkinson’s disease with normal olfactory function

    M. Rossi, A. Medina Escobar, A. Bril, P. Millar Vernetti, J.I. De Palo, D. Cerquetti, M. Merello (Buenos Aires, Argentina)

  • Motor fluctuations in relation to plasma concentrations following a single-dose of levodopa/carbidopa microtablets in advanced Parkinson’s disease

    M. Senek, H. Askmark, S.M. Aquilonius, F. Bergquist, R. Constantinescu, A. Ericsson, S. Lycke, A. Medvedev, M. Memedi, F. Ohlsson, J. Spira, J. Westin, D. Nyholm (Uppsala, Sweden)

  • Motor function restoration during REM sleep behavioral disorder in Parkinson’s disease: A vídeo-polysomnography study

    P. Bugalho, T. Lampreia, R. Miguel, M. Mendonça, A. Caetano, R. Barbosa (Lisbon, Portugal)

  • Motor phenotype classification in moderate to advanced PD: Data from the BioFIND study

    L. Luo, H.F. Andrews, J.G. Goldman, R.N. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, A. Amara, S. Frank, A. Rudolph, C. Casaceli, K. Gwinn, M. Sutherland, C. Kopil, L. Vincent, M. Frasier, U.J. Kang (New York, NY, USA)

  • Motor rigidity selectively associates with impaired odor identification in Parkinson’s disease

    J.D. Haugen, M.L.T.M. Muller, V. Kotagal, K.A. Frey, R.L. Albin, N.I. Bohnen (Ann Arbor, MI, USA)

  • Motor subtypes in Parkinson’s disease are distinguished by alterations in morphology and white matter integrity

    G. Vervoort, I. Leunissen, M. Firbank, E. Heremans, E. Nackaerts, W. Vandenberghe, A. Nieuwboer (Leuven, Belgium)

  • Motor symptoms in patients with early stages of Parkinson’s disease

    E.N. Gubanova, N.V. Fedorova (Moscow, Russia)

  • Motor variability and learning indices in DYT1 dystonia

    A. Sadnicka, A. Stevenson, J.C. Rothwell, K.P. Bhatia, J. Galea, M.J. Edwards (London, United Kingdom)

  • Motor-related brain changes associated with acute administration of trihexyphenidyl in patients with cervical dystonia

    R.G. Burciu, E. Ofori, P. Shukla, J.W. Chung, J. DeSimone, C.W. Hess, N.R. McFarland, A. Wagle Shukla, M.S. Okun, D.E. Vaillancourt (Gainesville, FL, USA)

  • Movement disorders (Parkinson’s disease) in Uzbekistan: Epidemiologic, clinical and therapeutic aspects

    N. Eshakulova, A. Umarov, N. Tuychibaeva, G. Rakhimbaeva, M. Ataniyazov (Tashkent, Uzbekistan)

  • Movement disorders after stroke in the third Moroccan level hospital, Marrakech

    A. Chahidi, M. Chraa, N. Kissani (Beni Mellal, Morocco)

  • Movement disorders are the common signs as the first neurological deficit in cases with spinocerebellar ataxia type 2 (SCA2)

    N. Miyaue, R. Ando, T. Iwaki, H. Yabe, N. Nishikawa, M. Nagai, H. Takashima, M. Nomoto (Ehime, Toohn City, Japan)

  • Movement disorders in diabetes – Report of two cases

    H. Sienkiewicz-Jarosz, G. Witkowski, M. Restel, D. Ryglewicz (Warszawa, Poland)

  • Movement disorders in patients with Japanese encephalitis: Experience in a tertiary care hospital in north eastern region of India

    A.R. Barua, N.C. Borah, P.S. Deb, A. Hatibaruah (Guwahati, India)

  • Movement execution but not preparation modulates somatosensory temporal discrimination thresholds in healthy subjects

    A. Conte, D. Belvisi, N. Manzo, F. Barone, M. Tartaglia, N. Upadhyay, M. Bologna, A. Berardelli (Rome, Italy)

  • Movement related beta oscillatory activity during self-paced wrist movement in the human subthalamic nucleus

    P. Zhuang, R. Chen, M. Hallett, Q. Cui, Y. Zhang, J. Li, Y. Li (Beijing, People's Republic of China)

  • mPower: A smartphone-based study of Parkinson’s disease provides personalized measures of disease impact

    A.D. Trister, E.C. Neto, B.M. Bot, T. Perumal, A. Pratap, A. Klein, E.R. Dorsey, C.M. Tanner, S.H. Friend (Seattle, WA, USA)

  • MR-guided high intensity focused ultrasound in Parkinson’s disease: A series of 5 cases

    N. Wegener, G. Kaegi, R. Bauer, B. Werner, E. Martin, S.R. Schreglmann, A. Lebeda, S. Haegele-Link (St. Gallen, Switzerland)

  • MRI abnormalities and EEG patterns of symptomatic epilepsy in children with cerebral palsy

    K. Aminov (Tashkent, Uzbekistan)

  • MRI diagnostics child cerebral palsy with symptomatic epilepsy

    D. Aminova (Tashkent, Uzbekistan)

  • MRI guided high-intensity focused ultrasond for the treatment of essential tremor and Parkinson’s disease: Clinical outcome and radiological findings of unilateral thalamotomy

    R. Martínez-Fernandez, J.A. Pineda-Pardo, M. del Álamo, F. Hernández, I. Obeso, S. Casas, P. Pastor, C. Oliver, L. Vela, J.A. Obeso (Madrid, Spain)

  • MRI signatures of the brain of Parkinson’s disease and idiopathic REM sleep behavioral disorder subjects

    P. Tuite, S. Mangia, P. Burton, A. Svatkova, I. Nestrasil, A. Sierra Lopez, K. Shmueli, L. Eberly, M. Howell, S. Michaeli (Minneapolis, MN, USA)

  • MRI-supported diagnosis of multiple system atrophy: Implications for clinical trials

    F. Krismer, G.K. Wenning, S. Bajaj, M. Schocke, C. Scherfler, W. Poewe, K. Seppi (Innsbruck, Austria)

  • Multi-modal imaging in Parkinson’s disease patients with freezing of gait

    J.M. Hall, C. O'Callaghan, J.M. Shine, M. Gilat, C.C. Walton, K.A. Ehgoetz Martens, A.A. Moustafa, S.J.G. Lewis (Milperra, Australia)

  • Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III

    B.L. Greco, T. Simuni, J. Lowell, K.C. Hodgeman, S. Sharma, C.A. Marshall, J. Denmark, W. Galpern, J.L. Goudreau, C. Meuiner, C. Sia, C.A. Thomas, D. Young, K.M. Biglan (Rochester, NY, USA)

  • Multi-parameter imaging in hemidystonia responsive to GPi deep brain stimulation

    C. Sidiropoulos, S. Bowyer, A. Zillgitt, P.A. LeWitt, H. Bagher-Ebadian, E. Davoodi-Bojd, J.M. Schwalb, H. Soltanian-Zadeh (West Bloomfield, MI, USA)

  • Multicenter report of clinical use of a non-motor symptom questionnaire for craniocervical dystonia: The DNMS quest

    L. Klingelhoefer, M. Kaiser, D. Martino, L. Perkins, M. Wienecke, A. Sauerbier, R. Untucht, D. Trivedi, K. Mammadova, T. Chiwera, A. Rizos, P. Martinez-Martin, H. Reichmann, K.R. Chaudhuri (Dresden, Germany)

  • Multicentre retrospective chart review of patients treated with incobotulinumtoxinA to evaluate sustained efficacy and tolerability in converted and de-novo conditions

    M.S. Jog, R.M. Jog, A. Tewari, D. Hobson, D. Stewart, D. King (London, ON, Canada)

  • Multidisciplinary group program integrating voice and dance movement therapy for Parkinson’s disease patients: Preliminary experience

    R. Peled, D. Shpunt, Y. Manor, M. Brozgol, A. Ezra, N. Hezi, R. Hen Simon, J.M. Hausdorff, T. Gurevich (Tel Aviv, Israel)

  • Multidisciplinary Parkinson rehabilitation in the Netherlands: The effectiveness of points of Parkinson (POP)

    E.T. Steendam-Oldekamp, W.A.W.F. Rutgers, T. van Laar (Groningen, Netherlands)

  • Multimodal imaging assessment of nigrostriatal pathway in Parkinson’s disease using 11C-PE2I PET and neuromelanin-sensitive MR

    A. Martin-Bastida, N.P. Lao-Kaim, A.A. Roussakis, W. Li, M. Politis, N. Valle-Guzman, Z. Kefalopoulou, G. Paul, H. Widner, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

  • Multimodal voxel-based analysis of the infratentorial brain region in Richardson’s syndrome, progressive supranuclear palsy-parkinsonism, Parkinson variant of multiple system atrophy and Parkinson’s disease

    M. Seki, C. Müller, E. Reiter, M. Nocker, M. Schocke, E. Gizewski, C. Kremser, G. Wenning, W. Poewe, K. Seppi, C. Scherfler (Innsbruck, Austria)

  • Multiple system atrophy with motor fluctuations: A presynaptic disease variant?

    Y. Compta, S.C. Cerquera, N. Falgàs, E. Gelpí, V. Puente, A. Cámara, L. Planellas, M.J. Martí, F. Valldeoriola (Barcelona, Spain)

  • Multiple system atrophy: A comparison between clinical subtypes

    L.B. Barcelos, R.A. Saba, S.M.A. Silva, V. Borges, H.B. Ferraz (Sao Paulo, Brazil)

  • Multiple-source current steering in bilateral subthalamic nucleus deep brain stimulation for Parkinson’s disease: Our experience

    J.M. Cardenas Prieto, P.A. Millan Giraldo (Cali, Colombia)

  • Muscle ceroid-lipofuscine-like deposits in a patient with FTD due to a progranulin mutation

    R. Terlizzi, M.L. Valentino, A. Bartoletti-Stella, M. Columbaro, S. Piras, P. Martinelli, P. Parchi, S. Capellari (Bologna, Italy)

  • Muscle selection patterns for injection of onabotulinumtoxinA in adult patients with post-stroke lower-limb spasticity influence outcome: Results from a double-blind, placebo-controlled phase 3 clinical trial

    T.H. Wein, A. Esquenazi, A.B. Ward, C. Geis, C. Liu, R. Dimitrova (Montreal, QC, Canada)

  • Musical ear syndrome as a presenting symptom of Lewy body disorder

    S.J. Song, D. Lee, Y.N. Kwon, T.B. Ahn (Seoul, Korea)

  • Mutant WDR45 links NBIA to impaired autophagy, mitochondrial dysfunction and oxidative stress

    M. Dulovic, S. Zittel, A. Rakovic, A. Westenberger, S. Biskup, A. Münchau, C. Klein, P. Seibler (Belgrade, Serbia)

  • Mutational analysis of GNAL gene in isolated dystonia patients from Spain

    P. Gómez-Garre, I. Huertas-Fernández, M.T. Cáceres-Redondo, A. Alonso-Canovas, I. Bernal-Bernal, A. Blanco-Ollero, M. Bonilla-Toribio, J.A. Burguera, M. Carballo, F. Carrillo, M.J. Catalán-Alonso, F. Escamilla-Sevilla, R. Espinosa-Rosso, M.C. Fernández-Moreno, J. García-Caldentey, J.M. García-Moreno, S. Giacometti-Silveira, J. Gutiérrez-García, S. Jesús-Maestre, E. López-Valdés, J.C. Martínez-Castrillo, M.P. Medialdea-Natera, C. Méndez-Lucena, A. Mínguez-Castellanos, M. Moya, J.J. Ochoa-Sepúlveda, T. Ojea, N. Rodríguez, I. Rubio-Agusti, M. Sillero-Sánchez, J. del Val, L. Vargas-González, P. Mir (Seville, Spain)

  • My PD Journey: Experiences reported by people with Parkinson’s disease in several European countries – A quantitative and qualitative study

    A. Schrag, O. Rascol, R. Merritt, S. Hotham, G. Bartl, L. Graham, On behalf of the European Parkinson's Disease Association (EPDA) and the Movement Disorder Society- European Section European Section (London, United Kingdom)

  • Myoclonus complicating chickenpox: A case report

    F. Imounan, N. Daoudi (Meknes, Morocco)

  • Myoclonus Dystonia: A report of two rare mutations

    A. Mahajan, C. Sidiropoulos (Detroit, MI, USA)

Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley